Shares of Ionis Pharmaceuticals Inc. were up over 8% in extended trading on Friday, following FDA approval of SPINRAZA, an antisense drug, for the treatment of spinal muscular atrophy in pediatric and adult patients. SPINRAZA, known generically as nusinersen, becomes the first and only treatment approved in the U.S. for SMA.
from RTT - Biotech http://ift.tt/2hS6RMx
via IFTTT
No comments:
Post a Comment